News

Kiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathy
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced the results from a preclinical study ...